How to Choose a CDMO for Oral Solid Dose Manufacturing

The short answer: The right oral solid dose (OSD) CDMO is the one whose process routes match yours (direct compression, wet or dry granulation, fluid-bed, coating, encapsulation, and for harder molecules hot-melt extrusion or spray drying), whose equipment train scales from your clinical batch to your commercial batch without a technology change, whose modified-release and dissolution capability covers your release profile, whose containment matches your compound's potency, and whose inspection record is clean on the findings that dominate OSD sites: cleaning validation, cross-contamination and data integrity. Price and region come after those five.

Oral solids are the largest category of medicines and the one every CDMO claims. That is exactly why selection fails: capability statements all read the same, and the differences that decide a programme (scale-independence of the equipment, depth in modified release, how the site handles a dissolution excursion) are only visible if you ask for them.

1. Match the process route, not the dosage form

"Tablets" is not a capability. The route is. Confirm the site runs, at your scale and with recent campaigns:

• Direct compression and dry granulation (roller compaction) for well-behaved, stable APIs.
• Wet granulation (high-shear and fluid-bed) with the drying capability your API's heat and moisture sensitivity needs.
• Coating (film, enteric, functional) with pan sizes that match your batch sizes.
• Encapsulation, including powder, pellet and liquid-fill if your formulation needs it.
• Modified release: matrix systems, coated pellets or minitablets, bilayer or multilayer tablets, osmotic systems if relevant.
• Enabling technologies for poorly soluble molecules: hot-melt extrusion, spray drying for amorphous solid dispersions, micronisation or nano-milling. Many general OSD sites do not have these in-house; find out whether they would sub-contract the critical step.

Ask for the last three products made by your route at your scale, and whether those campaigns are still running. A route that was run once five years ago is not current capability.

2. Check the scale path before the first batch

The expensive OSD failure is a process that works at 5 kg on one granulator and behaves differently at 200 kg on another. Map your programme's batch sizes from clinical through registration to commercial, and ask the site to show the equipment at each step and whether it is geometrically similar and scale-independent (same granulator family, same coating principle, same compression tooling design). A site that can take you from feasibility to commercial on one equipment family saves a technology transfer later; a site that cannot should say so, and you should plan the transfer from day one.

3. Formulation development depth and dissolution

If the formulation is not fixed, the site's formulation development group matters as much as the plant: pre-formulation characterisation, excipient compatibility, quality-by-design studies and a credible design space per ICH Q8(R2). For every OSD, dissolution is the release test that decides most investigations. Confirm the laboratory has the apparatus and method-development experience for your profile (immediate release, delayed, extended, biorelevant media), can run the comparative studies regulators expect when the process or site changes, and has a track record of resolving dissolution out-of-specification results with science rather than retesting.

4. Containment and segregation

Potent oral solids (hormones, oncology agents, low-dose compounds) need containment at dispensing, granulation, compression and coating that most general OSD suites were not built for; see the HPAPI guide for how to judge it. Even for non-potent products, ask how the site prevents cross-contamination between products in multi-product suites: dust extraction, cleaning validation limits derived from health-based exposure limits per EU GMP Chapters 3 and 5, and the changeover procedure. Cross-contamination and cleaning observations are among the most common findings at OSD sites.

5. Packaging, serialisation and the supply chain downstream

Bulk tablets are not a product. Confirm primary packaging capability (blisters, bottles, sachets) with the materials your stability data supports, serialisation and aggregation compliant with the US Drug Supply Chain Security Act and the EU Falsified Medicines Directive, and stability storage capacity in the ICH conditions your markets need. If the site packages elsewhere, every extra hand-off is a lead-time and a deviation risk.

6. Capacity, lead time and the commercial terms

OSD capacity is abundant in aggregate and scarce for specific routes at specific scales in specific windows. Ask for current lead times for your batch size, how the site prioritises between clients when capacity tightens, minimum batch and annual commitments, and how failed batches are treated commercially. Compare the quality agreement and the technical agreement side by side; the quality agreement decides who investigates and releases, the technical agreement decides who pays.

7. Regulatory record

Screen the site, not the brand: Form 483 observations, Warning Letters and recalls for the facility that will make your product, with attention to cleaning validation, cross-contamination, laboratory controls and data integrity, which together dominate OSD findings. A current GMP certificate proves an inspection took place; the enforcement history tells you what the inspectors found. PharmaTek's directory links each company to its FDA enforcement record so this screen takes minutes, and the regions comparison explains what the cost gap between Indian, European and US sites does and does not include.

Questions that expose a weak fit

1. "Which three products have you made by our process route at our scale in the last two years?"
2. "Show us the equipment train from our clinical batch size to our commercial batch size. Where does the technology change?"
3. "How many dissolution OOS investigations did you close last year, and what were the root causes?"
4. "What is the cleaning limit for the product currently in the suite you propose, and how was it derived?"
5. "What are your current lead times for a batch of our size, and what happened to lead times the last time capacity tightened?"
6. "Which of your last three FDA or EU inspections produced observations, and what changed as a result?"

Where to find candidates

Shortlist by dosage form, route and country in PharmaTek's directory, where each profile carries its FDA enforcement record and GMP certificates on record, or hand the brief to the Sourcing Desk for a vendor-neutral, compliance-screened shortlist for a fixed fee. The general CDMO selection checklist covers the commercial and quality questions common to every modality.

Frequently asked questions

What should you look for in an oral solid dose CDMO? Current experience with your specific process route at your scale, an equipment train that scales without a technology change, formulation and dissolution capability matched to your release profile, containment and cross-contamination controls appropriate to your compound, in-house packaging and serialisation, realistic lead times, and a clean inspection record on cleaning validation, cross-contamination and data integrity.

Which is harder to outsource: immediate-release or modified-release tablets? Modified release. Matrix, coated-pellet, multilayer and osmotic systems depend on process parameters and excipient functionality that are sensitive to scale and equipment, and dissolution profiles have to be reproduced, not just met. Fewer CDMOs have deep modified-release experience; ask for products, not capabilities.

How do you avoid scale-up problems with tablets? Map batch sizes from clinical to commercial at the start and choose a site whose equipment family is geometrically similar across those sizes. Identify scale-dependent parameters during development, run engineering batches at the new scale before registration batches, and treat any change of granulator, dryer or coater type as a technology transfer with its own comparability study.

Are Indian CDMOs good for oral solid dose? India has the deepest base of oral solid dose and generics capacity in the world and a large share of US Drug Master Files and EU Certificates of Suitability, at the lowest cost. The spread of site-level quality is also wide, so the screen has to be done site by site on inspection history; the average between regions matters less than the record of the specific facility.

What inspection findings are most common at oral solid dose sites? Cleaning validation and cross-contamination controls in multi-product suites, laboratory controls including dissolution and out-of-specification handling, and data integrity in electronic records. These categories appear repeatedly in FDA Form 483s and Warning Letters to oral solid manufacturers and are where diligence should concentrate.

---

Ready to shortlist? Filter the directory by country and capability with FDA signals on every profile, or send your product and volume to the Sourcing Desk.